<DOC>
	<DOCNO>NCT03085810</DOCNO>
	<brief_summary>This prospective , multicenter , open-label , single-arm , phase 3b study evaluate effectiveness safety ocrelizumab participant early stage RRMS . The study consist open-label treatment period 192 week follow-up period least 48 week .</brief_summary>
	<brief_title>Study Evaluate Effectiveness Safety Ocrelizumab Participants With Early Stage Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Have definite diagnosis RRMS , per revise McDonald 2010 criterion Have length disease duration , first document clinical attack consistent MS disease less equal ( &lt; /= ) 3 year Within last 12 month one clinically report relapse ( ) one sign MRI activity EDSS 0.0 3.5 inclusive , screen An agreement use acceptable birth control method woman childbearing potential , treatment period least 6 month last dose study drug Secondary progressive multiple sclerosis ( SPMS ) history primary progressive progressive relapse MS Inability complete MRI Known presence neurological disorder Exclusions Related General Health : Pregnancy lactation Any concomitant disease may require chronic treatment systemic corticosteroid immunosuppressant course study History currently active primary secondary immunodeficiency Lack peripheral venous access History severe allergic anaphylactic reaction humanize murine monoclonal antibody Significant uncontrolled somatic disease significant disease may preclude participant participate study Congestive heart failure ( New York Heart Association [ NYHA ] III IV functional severity ) Known active bacterial , viral , fungal , mycobacterial infection infection , ( exclude fungal infection nail bed ) major episode infection require hospitalization treatment intravenous ( IV ) antibiotic within 4 week prior screen oral antibiotic 2 week prior screen History malignancy , major opportunistic infection , alcohol drug abuse , recurrent chronic infection , and/or coagulation disorder Exclusions Related Medications : Received prior approve disease modify treatment ( DMT ) label MS , example , interferon , glatiramer acetate , natalizumab , alemtuzumab , daclizumab , fingolimod , teiflunomide dimethylfumarate Receipt vaccine within 6 week prior baseline visit Previous treatment Bcell target therapy ( i.e. , rituximab , ocrelizumab , atacicept , belimumab , ofatumumab ) Any previous treatment immunosuppressants/ immunomodulators/ antineoplastic therapy ( cyclophosphamide , azathioprine , mycophenolate mofetil , cyclosporine , methotrexate , cladribine , mitoxantrone , laquinimod , total body irradiation , bone marrow transplantation ) Treatment investigational DMT Treatment fampridine/dalfamipridine unless stable dose &gt; /=30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>